Score
2
2013
pubmed
[Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results].
Khavinson. V Kh VKh; Kuznik. B I BI; Ryzhak. G A GA
Key Findings
- Vilon is listed among peptides claimed to support healthy aging and disease prevention
- The authors report positive effects of peptide bioregulators across different age groups in their own long‑term studies
- The review emphasizes the potential of these peptides as geroprotectors but lacks specific quantitative results
Practical Outcomes
- The take‑away is that Vilon and similar peptides are being explored for anti‑aging benefits, but the evidence presented is too general to form a concrete self‑experiment protocol. Enthusiasts should treat these claims as preliminary and wait for detailed dosage and safety data before using them.
Summary
The paper reviews long‑term clinical work on several peptide bioregulators, including Vilon, saying they may help prevent age‑related diseases and act as “geroprotectors,” but it doesn’t give clear dosing or protocol details.
Abstract
The review summarizes the results of long-term studies of the authors on the clinical efficacy of peptide bioregulators (Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin) for the prevention of diseases and treatment of people of different age. Special attention is given to the analysis of the use of peptide bioregulators as geroprotectors.
Study Information
Provider
pubmed
Year
2013